Now enrolling

Iovance is currently recruiting patients with different types of cancer to participate in clinical trials. Throughout the TIL treatment journey, Iovance provides individualized support for patients and physicians through IovanceCares™, a proprietary system that enables communication and coordination with healthcare providers.

 

Learn more about TIL therapy

Learn more about PBL therapy

Clinical trial overview

tumor

IOV-COM-202 is a Phase 2 clinical trial of Iovance TIL therapy (lifileucel, LN-145, LN-144 and LN-145-S1). It is enrolling patients who have been diagnosed with histologically confirmed unresectable or metastatic melanoma, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), recurrent or metastatic non-small cell lung cancer (NSCLC) or relapsed or refractory NSCLC.

To learn more about the trial, please call

1-866-565-4410

Further details for healthcare providers can be accessed below:

www.clinicaltrials.gov


Clinical trial overview

icon

IOV-LUN-202 is a Phase 2 clinical trial of Iovance TIL therapy (LN-145), enrolling patients who have been diagnosed with histologically confirmed recurrent or metastatic NSCLC.

 

Learn more about this clinical trial

To learn more about the trial, please call

1-866-565-4410

Further details for healthcare providers can be accessed below:

www.clinicaltrials.gov


Clinical trial overview

icon

C-145-04 is a Phase 2 clinical trial enrolling patients with recurrent, metastatic or persistent cervical cancer. The clinical trial was designed to determine whether Iovance investigational TIL therapy lifileucel is safe and effective for the treatment of recurrent, metastatic or persistent cervical carcinoma.

To learn more about the trial, please call

1-866-565-4410

Further details for healthcare providers can be accessed below:

www.clinicaltrials.gov


Clinical trial overview

icon

IOV-GM1-201 is Phase 1/2 study to evaluate the safety and efficacy of IOV-4001, a genetically modified autologous PD-1 knockout tumor-infiltrating lymphocytes (TIL) product, in patients with unresectable or metastatic melanoma, or stage III or IV non-small-cell lung cancer.

To learn more about the trial, please call

1-866-565-4410

Further details for healthcare providers can be accessed below:

www.clinicaltrials.gov


Clinical trial overview

icon

IOV-CLL-01 is a Phase 1/2 study to evaluate the safety and efficacy of autologous PBL (peripheral blood lymphocytes) therapy IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

To learn more about the trial, please call:

1-866-565-4410

Further details for healthcare providers can be accessed below:

www.clinicaltrials.gov


View Our Expanded Access Policy

TIL and PBL therapies are investigational therapies that have not been approved for any indication by the Food and Drug Administration (FDA) or any other regulatory agency. The safety and efficacy of these therapies have not been determined.